Press Releases

02 May 2019

Kaleido Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

LEXINGTON, Mass. , May 02, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced financial

12 Apr 2019

Kaleido Biosciences Announces Presentation of Clinical Study and Ex Vivo Data Supporting the Development of Novel Microbiome Metabolic Therapies for Hyperammonemia at The International Liver Congress™ 2019 (EASL)

LEXINGTON, Mass. , April 12, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today presented

08 Apr 2019

Kaleido Biosciences Announces Key Appointments to Leadership Team

Johan van Hylckama Vlieg, Ph.D., Named Chief Scientific Officer and Clare Fisher Appointed Chief Business Officer LEXINGTON, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc . (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to

27 Mar 2019

Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)

Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass. , March 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated,

21 Mar 2019

Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis

Studies are evaluating novel Microbiome Metabolic Therapies, KB195 and KB174, in target patient populations; data expected in Q4 2019 Third non-IND clinical study in healthy subjects also underway to evaluate dosing of KB174 LEXINGTON, Mass. , March 21, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences,

08 Mar 2019

Kaleido Biosciences to Highlight its Platform to Identify and Evaluate Microbiome Metabolic Therapies to Reduce Gut Ammonia Production in Presentation at Keystone Symposia on Microbiome

LEXINGTON, Mass. , March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences , (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced that a

04 Mar 2019

Kaleido Biosciences Announces Closing of Initial Public Offering

LEXINGTON, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the

27 Feb 2019

Kaleido Biosciences Announces Pricing of Initial Public Offering

LEXINGTON, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the microbiome organ to treat disease and improve human health, today announced the